REFERENCES
  1. Adamson S (1985) Through the gateway of the heart: Accounts of experiences with MDMA and other empathogenic substances. Four Trees Publications, San Francisco, CA.
  2. Blake DD, Owens MD, & Keane TM (1990). Increasing group attendance on a psychiatric unit: an alternating treatments design comparison. J Behav Ther Exp Psychiatry, 21: 15-20
  3. Brady K, Killeen T, Saladin M, Dansky B, & Becker S (1994). Comorbid substance abuse and posttraumatic stress disorder: characteristics of women in treatment. American Journal of Addiction, 3, 160-164
  4. Cami J, Farre M, Mas M, Roset PN, Poudevida S, Mas A, San L, de la Torre R (2000) Human pharmacology of 3,4-methylenedioxymethamphetamine ("ecstasy"): psychomotor performance and subjective effects. J Clin Psychopharmacol 20: 455-466
  5. Davis M, Walker DL, Lee Y (1997) Amygdala and bed nucleus of the stria terminalis: differential roles in fear and anxiety measured with the acoustic startle reflex. Philos Trans R Soc Lond B Biol Sci 352: 1675-1687
  6. d'Otalora, M. MDMA and LSD Therapy in the Treatment of Post Traumatic Stress Disorder in a Case of Sexual Abuse http://www.maps.org/research/mdma/moaccount.html
  7. Downing J (1986) The psychological and physiological effects of MDMA on normal volunteers. J Psychoactive Drugs 18: 335-340
  8. Dunn BG and Greene E (2002) Voices, A History of Body Psychotherapy. USA Body Psychotherapy Journal, 1: 53-117
  9. Faustman, WO & White, PA (1989). Diagnostic and psychopharmacological treatment characteristics of 536 inpatients with posttraumatic stress disorder. J Nerv Ment Dis, 177(3), 154-159
  10. First MB, Spitzer R, Gibbon M, & Williams J (1994). Structured clinical interview for Axis I DSM-IV disorders. Patient Edition (SCID-I/P, vs 2.0)
  11. Foa, F.B., Keane, T.M., & Friedman, M.J. (2000). Introduction. In Foa, F.B. et al (Eds), Effective Treatments for PTSD (pp.1-17). New York: Guilford Press.
  12. Foa FB, Rothbaum BO, Furr JM. (2003) Augmenting Exposure Therapy with other CBT Procedures. Psychiatric Annals, 33(1) 47-53.
  13. Fox HC, Toplis AS, Turner JJD, Parrott AC (2001) Auditory verbal learning in drug-free polydrug users. Human Psychopharmacol Clin Exp, 16: 613-618
  14. Fox, HC, Parrott, AC and Turner, JJD (2001) Ecstasy use; Cognitive deficits related to dosage rather than to self-reported problematic use of the drug. J of Psychopharmacology, 15: 273-281
  15. Gamma A, Buck A, Berthold T, Liechti ME, Vollenweider FX (2000) 3,4- Methylenedioxymethamphetamine (MDMA) modulates cortical and limbic brain activity as measured by [H(2)(15)O]-PET in healthy humans. Neuropsychopharmacology 23: 388-395
  16. Gasser P (1994) Psycholytic Therapy with MDMA and LSD in Switzerland. MAPS Newsletter 5: 3-7
  17. Gouzoulis-Mayfrank, E, Daumann J, Tuchtenhagen F, Pelz S, Becker S, Kunert HJ, Fimm B, Sass H (2000) Impaired cognitive performance in drug free users of recreational ecstasy (MDMA). J Neurol Neurosurg Psychiatry 68: 719-725
  18. Greenspan M (1995) Out of bounds. Common Boundary, July/August; 51-58
  19. Greer G, Tolbert RA (1986) Subjective reports of the effects of MDMA in a clinical setting. J Psychoactive Drugs 18: 319-327
  20. Greer GR, Tolbert R (1998) A method of conducting therapeutic sessions with MDMA. J Psychoactive Drugs 30: 371-379
  21. Grinspoon L, Bakalar JB (1986) Can drugs be used to enhance the psychotherapeutic process? Am J Psychother 40: 393-404
  22. Grinspoon L, Doblin R (2001) Psychedelics as catalysts in insight-oriented psychotherapy. Social Research, 68; 677-695
  23. Grob CS and Poland RE (1997). MDMA. In Lowinson JH, Ruiz P, Millman RB , Langrod JG (Eds.) Substance Abuse: A comprehensive textbook, 3rd Ed (pp. 269-275). Willians and Wilkins, Baltimore MD,
  24. Grob CS, Poland RE, Chang L, Ernst T (1996) Psychobiologic effects of 3,4- methylenedioxymethamphetamine in humans: methodological considerations and preliminary observations. Behav Brain Res 73: 103-107
  25. Grof S (2001; 1980) LSD Psychotherapy. Multidisciplinary Association for Psychedelic Studies, Sarasota FL.
  26. Grof S (2000) The Psychology of the Future. SUNY Press, Albany, NY.
  27. Harris DS, Baggott M, Mendelson J, Mendelson JE, Jones RT (2002). Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl). 162: 396-405
  28. Horvath AO and Greenberg LS (1989). Development and validation of the Working Alliance Inventory. Journal of Counseling Psychology, 36 (2), 223-233
  29. Horowitz M, Wilner N, & Alvarez W (1979). Impact of Event Scale: a measure of subjective stress. Psychosom Med, 41, 209-218
  30. Jaycox, LH, Zoellner L, Foa EB, (2002) Cognitive-Behavior Therapy for PTSD in Rape Survivors. Journal of Clinical Psychology, 58(8) 891 - 906.
  31. Johnson SM (1996) Emotion focused couple therapy with trauma survivors; Strengthening attachment bonds. Guilford Press: New York NY.
  32. Krupnick JL. (2002) Brief Psychodynamic Treatment of PTSD. Journal of Clinical Psychology, 58(8) 919-932.
  33. Lester SJ, Baggott M, Welm S, Schiller NB, Jones RT, Foster E, Mendelson J (2000) Cardiovascular effects of 3,4-methylenedioxymethamphetamine. A double- blind, placebo-controlled trial. Ann Intern Med 133: 969-973
  34. Liechti ME, Gamma A, Vollenweider FX (2001a) Gender differences in the subjective effects of MDMA. Psychopharmacology, 154: 161-168
  35. Mas M, Farre M, de la Torre R, Roset PN, Ortuno J, Segura J, Cami J (1999) Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther 290: 136-145
  36. Metzner R, Adamson S (2001) Using MDMA in Healing, Psychotherapy and Spiritual Practice. In Holland J (Ed). Ecstasy: The complete guide. (pp. 182-207). Inner Traditions: Rochester VT. Originally published in ReVision 10(4) (1988) The nature of the MDMA experience and its role in healing, psychotherapy and spiritual practice.
  37. Milakovich J (1998) Differences between therapists who touch and those who do not. In Smith EW, Chance NR, Imes S (Eds).Touch in Psychotherapy. (pp. 74-91) The Guilford Press: New York, NY.
  38. Mitrushina, Maura N; Boone, Kyle Brauer; D'Elia, Louis F.(1999). Handbook of normative data for neuropsychological assessment. Oxford University Press, New York, NY.
  39. Montgomery S & Bech P (2000) ECNP consensus meeting, March 5-6, 1999, Nice. Post traumatic stress disorder: guidelines for investigating efficacy of pharmacological intervention. ECNP and ECST. European Neuropsychopharmacology. 10: 297-303
  40. Morgan MJ (1999) Memory deficits associated with recreational use of "ecstasy" (MDMA). Psychopharmacology (Berl) 141: 30-36
  41. Naranjo C (2001) Experiences with the interpersonal psychedelics. In Holland J. (Ed) Ecstasy: The Complete Guide. (pp. 208-221) Inner Traditions; Rochester VT.
  42. Piedmont, Ralph L. (1998). The revised NEO Personality Inventory: Clinical and research applications. Plenum Press, NewYork, NY.
  43. Rasmusson AM, Charney DS (1997) Animal models of relevance to PTSD. Ann N Y Acad Sci 821: 332-351
  44. Rodgers, J. (2000). Cognitive performance amongst recreational users of "ecstasy." Psychopharmacology, 151, 19-24
  45. Randolph, C. (1998). Repeatable Battery for the Assessment of Neuropsychological Status manual. The Psychological Corporation, San Antonio, TX.
  46. Roman, Deborah D; Edwall, Glenace E; Buchanan, Rebecca J; Patton, Jim H. (1991). Extended norms for the paced auditory serial addition task. Clinical Neuropsychologist, 5: 33-40
  47. Styk J (2001) MDMA Therapy in Switzerland. From site: http://www.inch.com/~jholland/newuploads/styk.htm Published on-line: Date unknown, prob. between Aug-Nov 2001
  48. Tancer ME, and Johnson C-E (2001). The subjective effects of MDMA and mCPP in moderate MDMA users. Drug Alcohol Depend, 65: 97-101
  49. Urasano J et al, American Journal of Psychiatry Supplement, v 161, n. 11, November 2004
  50. Vollenweider, FX, Gucker, P., Schönbächler, R, Kamber, E, Vollenweider- Scherpenhuyzen, MFI, Schubiger, G, & Hell, D (2000). Effects of MDMA on 5-HT uptake sites using PET and [11C]-McN5652 in humans. Data presented at 2000 conference of the German Society for Psychiatry, Psychotherapy and Neuromedicine [Deutsche Gesellschaft für psychiatrie, Psychotherapie und Nervenheilkunde]
  51. Vollenweider FX, Gamma A, Liechti M, Huber T (1998) Psychological and cardiovascular effects and short-term sequelae of MDMA ("ecstasy") in MDMA-naive healthy volunteers. Neuropsychopharmacology 19: 241-251
  52. White KE (2002) A study of ethical and clinical implications for the appropriate use of touch in psychotherapy. USA Body Psychotherapy Journal, 1; 16-41
  53. Widmer S (1997) Listening into the heart of things: The awakening of love: On MDMA and LSD: The undesired psychotherapy. Basic Editions, Basic Editions.
  54. Wolfson PE (1986) Meetings at the edge with Adam: A man for all seasons? Journal of Psychoactive Drugs 18: 329-333